• Twitter
  • Linkedin
  • Careers
  • News
  • Contact
Amplyx
  • Who We Are
  • Our Focus
  • Our Pipeline
  • Patient Community
  • Investors
  • Menu

Press Release Archive

All/2018/2019/2020/Press Release
December 3, 2020/by ksmith

Amplyx Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting

October 16, 2020/by ksmith

Amplyx to Present New Clinical and Preclinical Data for its Two Lead Programs at Upcoming Scientific Conferences

September 14, 2020/by ksmith

Amplyx to Participate in Upcoming Antifungal Webinar Presented by Maxim Group LLC

August 17, 2020/by ksmith

Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients

August 5, 2020/by ksmith

Amplyx Pharmaceuticals Announces Participation in Multiple Upcoming Investor Conferences

July 22, 2020/by ksmith

Amplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix

June 24, 2020/by ksmith

Amplyx Pharmaceuticals to Present at the Upcoming Virtual European Biotech Investor Day 2020

June 8, 2020/by eallison

Amplyx Pharmaceuticals Expands Executive Leadership Team

May 19, 2020/by ksmith

Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million

May 19, 2020/by ksmith

Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix

April 29, 2020/by ksmith

Amplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector

September 24, 2019/by eallison

Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)

September 16, 2019/by eallison

Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients

September 16, 2019/by eallison

Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia

September 9, 2019/by eallison

FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications

April 12, 2019/by Lauren Fish

Amplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam

February 11, 2019/by eallison

FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis

January 31, 2019/by eallison

Antimicrobials Working Group Announces Updates to Leadership Team

November 12, 2018/by eallison

Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection

June 7, 2018/by eallison

Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host

June 5, 2018/by eallison

Amplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference

April 30, 2018/by eallison

Amplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species

November 12, 2018/by eallison

Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection

June 7, 2018/by eallison

Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host

June 5, 2018/by eallison

Amplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference

April 30, 2018/by eallison

Amplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species

September 24, 2019/by eallison

Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)

September 16, 2019/by eallison

Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients

September 16, 2019/by eallison

Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia

September 9, 2019/by eallison

FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications

April 12, 2019/by Lauren Fish

Amplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam

February 11, 2019/by eallison

FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis

January 31, 2019/by eallison

Antimicrobials Working Group Announces Updates to Leadership Team

December 3, 2020/by ksmith

Amplyx Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting

October 16, 2020/by ksmith

Amplyx to Present New Clinical and Preclinical Data for its Two Lead Programs at Upcoming Scientific Conferences

September 14, 2020/by ksmith

Amplyx to Participate in Upcoming Antifungal Webinar Presented by Maxim Group LLC

August 17, 2020/by ksmith

Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients

August 5, 2020/by ksmith

Amplyx Pharmaceuticals Announces Participation in Multiple Upcoming Investor Conferences

July 22, 2020/by ksmith

Amplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix

June 24, 2020/by ksmith

Amplyx Pharmaceuticals to Present at the Upcoming Virtual European Biotech Investor Day 2020

June 8, 2020/by eallison

Amplyx Pharmaceuticals Expands Executive Leadership Team

May 19, 2020/by ksmith

Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million

May 19, 2020/by ksmith

Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix

April 29, 2020/by ksmith

Amplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector

December 3, 2020/by ksmith

Amplyx Announces Upcoming Virtual Data Presentations at 62nd American Society of Hematology (ASH) Annual Meeting

October 16, 2020/by ksmith

Amplyx to Present New Clinical and Preclinical Data for its Two Lead Programs at Upcoming Scientific Conferences

September 14, 2020/by ksmith

Amplyx to Participate in Upcoming Antifungal Webinar Presented by Maxim Group LLC

August 17, 2020/by ksmith

Amplyx Doses First Patient in Phase 2 Clinical Trial of Anti-BKV Monoclonal Antibody in Renal Transplant Recipients

August 5, 2020/by ksmith

Amplyx Pharmaceuticals Announces Participation in Multiple Upcoming Investor Conferences

July 22, 2020/by ksmith

Amplyx Announces Positive Top-line Data in Phase 2 Clinical Trial of Novel Antifungal Fosmanogepix

June 24, 2020/by ksmith

Amplyx Pharmaceuticals to Present at the Upcoming Virtual European Biotech Investor Day 2020

May 19, 2020/by ksmith

Amplyx Pharmaceuticals Adds Pfizer and Adage to Series C Financing, Bringing Total to over 90 Million

May 19, 2020/by ksmith

Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix

April 29, 2020/by ksmith

Amplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector

September 24, 2019/by eallison

Amplyx Announces Presentations on Fosmanogepix (APX001) at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9)

September 16, 2019/by eallison

Amplyx Pharmaceuticals Licenses Phase 2 Drug Candidate for BK Viral Disease in Transplant Patients

September 16, 2019/by eallison

Amplyx Pharmaceuticals Announces Positive Preliminary Data from Ongoing Fosmanogepix Phase 2 Study in Candidemia

September 9, 2019/by eallison

FDA Grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for Seven Different Indications

April 12, 2019/by Lauren Fish

Amplyx Pharmaceuticals Announces Presentations at the 29th ECCMID in Amsterdam

February 11, 2019/by eallison

FDA Grants Orphan Drug Designation to Amplyx Pharmaceuticals for APX001 for Treatment of Cryptococcosis

January 31, 2019/by eallison

Antimicrobials Working Group Announces Updates to Leadership Team

November 12, 2018/by eallison

Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection

June 7, 2018/by eallison

Amplyx Announces Presentations on APX001 at American Society for Microbiology Microbe 2018 and the 20th Symposium on Infections in the Immunocompromised Host

June 5, 2018/by eallison

Amplyx Pharmaceuticals to Participate in BIO International Convention Panel and Present at Jefferies Global Healthcare Conference

April 30, 2018/by eallison

Amplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species

Amplyx © Copyright 2021 Privacy Policy EU Privacy Policy
Scroll to top